Surrozen (SRZN) Competitors $8.40 -0.01 (-0.12%) Closing price 04:00 PM EasternExtended Trading$8.46 +0.05 (+0.65%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SRZN vs. RNAC, FHTX, GOSS, AARD, ZYBT, TRDA, TKNO, SGMT, PVLA, and CRVSShould you be buying Surrozen stock or one of its competitors? The main competitors of Surrozen include Cartesian Therapeutics (RNAC), Foghorn Therapeutics (FHTX), Gossamer Bio (GOSS), Aardvark Therapeutics (AARD), Zhengye Biotechnology (ZYBT), Entrada Therapeutics (TRDA), Alpha Teknova (TKNO), Sagimet Biosciences (SGMT), Palvella Therapeutics (PVLA), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry. Surrozen vs. Its Competitors Cartesian Therapeutics Foghorn Therapeutics Gossamer Bio Aardvark Therapeutics Zhengye Biotechnology Entrada Therapeutics Alpha Teknova Sagimet Biosciences Palvella Therapeutics Corvus Pharmaceuticals Cartesian Therapeutics (NASDAQ:RNAC) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation. Which has preferable earnings and valuation, RNAC or SRZN? Surrozen has lower revenue, but higher earnings than Cartesian Therapeutics. Surrozen is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCartesian Therapeutics$38.91M8.85-$77.42M-$52.83-0.25Surrozen$10.65M6.75-$63.56M-$24.96-0.34 Which has more risk and volatility, RNAC or SRZN? Cartesian Therapeutics has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Is RNAC or SRZN more profitable? Cartesian Therapeutics' return on equity of 0.00% beat Surrozen's return on equity.Company Net Margins Return on Equity Return on Assets Cartesian TherapeuticsN/A N/A -7.01% Surrozen N/A -842.90%-71.32% Do analysts rate RNAC or SRZN? Cartesian Therapeutics presently has a consensus price target of $40.00, indicating a potential upside of 201.43%. Surrozen has a consensus price target of $38.50, indicating a potential upside of 358.33%. Given Surrozen's stronger consensus rating and higher possible upside, analysts clearly believe Surrozen is more favorable than Cartesian Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Surrozen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor RNAC or SRZN? In the previous week, Cartesian Therapeutics had 6 more articles in the media than Surrozen. MarketBeat recorded 7 mentions for Cartesian Therapeutics and 1 mentions for Surrozen. Surrozen's average media sentiment score of 1.87 beat Cartesian Therapeutics' score of 0.95 indicating that Surrozen is being referred to more favorably in the news media. Company Overall Sentiment Cartesian Therapeutics Positive Surrozen Very Positive Do insiders & institutionals believe in RNAC or SRZN? 87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 60.3% of Cartesian Therapeutics shares are held by insiders. Comparatively, 45.2% of Surrozen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryCartesian Therapeutics beats Surrozen on 9 of the 15 factors compared between the two stocks. Get Surrozen News Delivered to You Automatically Sign up to receive the latest news and ratings for SRZN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRZN vs. The Competition Export to ExcelMetricSurrozenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$72.05M$2.42B$5.52B$9.32BDividend YieldN/A1.79%4.25%4.05%P/E Ratio-0.349.1828.1519.68Price / Sales6.75737.05438.33100.29Price / CashN/A160.6835.5357.53Price / Book-1.284.698.235.67Net Income-$63.56M$30.99M$3.23B$257.51M7 Day Performance0.96%0.60%-0.01%0.52%1 Month Performance-11.95%7.93%5.61%8.84%1 Year Performance-11.58%-5.48%26.52%14.18% Surrozen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRZNSurrozen2.7539 of 5 stars$8.40-0.1%$38.50+358.3%-10.0%$72.05M$10.65M-0.3480Positive NewsRNACCartesian Therapeutics2.2281 of 5 stars$11.05+2.6%$40.67+268.0%-24.2%$286.75M$38.91M-0.2164FHTXFoghorn Therapeutics2.0912 of 5 stars$5.05+5.6%$12.13+140.1%-7.2%$281.49M$22.60M-3.71120GOSSGossamer Bio3.7769 of 5 stars$1.24-1.2%$7.33+493.8%+22.9%$280.72M$114.70M-5.37180News CoveragePositive NewsAnalyst ForecastGap UpAARDAardvark TherapeuticsN/A$12.70-8.8%$33.00+159.8%N/A$275.54MN/A0.0018ZYBTZhengye BiotechnologyN/A$5.78+4.3%N/AN/A$272.62M$189.75M0.00278Gap DownTRDAEntrada Therapeutics3.3089 of 5 stars$7.16+2.7%$25.67+258.5%-64.3%$271.74M$172.22M8.84110TKNOAlpha Teknova2.0269 of 5 stars$5.08+1.8%$8.50+67.3%+243.8%$271.48M$37.74M-10.58240Positive NewsSGMTSagimet Biosciences2.8208 of 5 stars$8.85+2.0%$26.60+200.6%+179.1%$271.43M$2M-5.038News CoveragePositive NewsPVLAPalvella Therapeutics2.5094 of 5 stars$24.39-2.0%$46.29+89.8%N/A$269.75M$42.81M-2.02N/ACRVSCorvus Pharmaceuticals2.8374 of 5 stars$3.94+1.0%$15.00+280.7%+108.5%$268.59MN/A-4.0230Positive News Related Companies and Tools Related Companies RNAC Competitors FHTX Competitors GOSS Competitors AARD Competitors ZYBT Competitors TRDA Competitors TKNO Competitors SGMT Competitors PVLA Competitors CRVS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRZN) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredTrump has to finance $21 trillion. Here’s His Move…Trump needs $21 trillion to fund his agenda — and insiders believe he’s quietly preparing a major shift in the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surrozen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surrozen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SRZN Stock Alerts